Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology

Author's Avatar
Jun 02, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR+European+Congress+of+Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant.